AU2018300091B2 - Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors - Google Patents

Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors Download PDF

Info

Publication number
AU2018300091B2
AU2018300091B2 AU2018300091A AU2018300091A AU2018300091B2 AU 2018300091 B2 AU2018300091 B2 AU 2018300091B2 AU 2018300091 A AU2018300091 A AU 2018300091A AU 2018300091 A AU2018300091 A AU 2018300091A AU 2018300091 B2 AU2018300091 B2 AU 2018300091B2
Authority
AU
Australia
Prior art keywords
spiro
dihydro
quinazoline
chloro
cyclohexane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018300091A
Other languages
English (en)
Other versions
AU2018300091A1 (en
Inventor
Mi Chen
DeMichael CHUNG
Vincent John Santora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dart Neuroscience LLC
Original Assignee
Dart Neuroscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience LLC filed Critical Dart Neuroscience LLC
Publication of AU2018300091A1 publication Critical patent/AU2018300091A1/en
Application granted granted Critical
Publication of AU2018300091B2 publication Critical patent/AU2018300091B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018300091A 2017-07-12 2018-07-11 Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors Active AU2018300091B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531802P 2017-07-12 2017-07-12
US62/531,802 2017-07-12
PCT/US2018/041565 WO2019014305A1 (en) 2017-07-12 2018-07-11 SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS

Publications (2)

Publication Number Publication Date
AU2018300091A1 AU2018300091A1 (en) 2020-01-30
AU2018300091B2 true AU2018300091B2 (en) 2023-06-22

Family

ID=63036485

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018300091A Active AU2018300091B2 (en) 2017-07-12 2018-07-11 Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors

Country Status (9)

Country Link
US (2) US11685745B2 (enExample)
EP (1) EP3652180B1 (enExample)
JP (1) JP7213863B2 (enExample)
KR (1) KR102640696B1 (enExample)
CN (1) CN111094293B (enExample)
AU (1) AU2018300091B2 (enExample)
CA (1) CA3069432A1 (enExample)
MX (1) MX2020000295A (enExample)
WO (1) WO2019014305A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3652180B1 (en) 2017-07-12 2023-11-29 Dart NeuroScience, LLC Substituted benzoxazole and benzofuran compounds as pde7 inhibitors
JP2022541954A (ja) * 2019-07-17 2022-09-28 小野薬品工業株式会社 Ｋｄｍ５阻害活性を有する化合物およびその医薬用途
CN112574202B (zh) * 2020-12-11 2021-11-09 台州学院 一种螺喹唑啉-2-酮类衍生物及其制备方法和应用
CA3264002A1 (en) * 2022-08-18 2024-02-22 Mitodicure Gmbh USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITING ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERCISE INTOLERANCE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074754A1 (en) * 2001-03-21 2002-09-26 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
WO2007063391A2 (en) * 2005-12-02 2007-06-07 Pfizer Limited Spirocyclic quinazoline derivatives as pde7 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7491742B2 (en) 1999-10-21 2009-02-17 Merck Patent Gmbh Imidazole derivatives as phosphodiesterase VII inhibitors
DE19953025A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Pyrrolderivate als Phosphodiesterase VII-Hemmer
DE19953024A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
DE19953414A1 (de) 1999-11-06 2001-05-10 Merck Patent Gmbh Imidazopyridinderivate als Phospodiesterase VII-Hemmer
DE19954707A1 (de) 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
US20030138815A1 (en) 2000-04-28 2003-07-24 Franz-Werner Kluxen Splice variant of camp phosphodiesterase type7(pde7a3)
GB0015095D0 (en) 2000-06-20 2000-08-09 Celltech Chiroscience Ltd Chemical compounds
CN100430401C (zh) 2000-07-11 2008-11-05 Amr科技公司 新的4-苯基取代的四氢异喹啉类化合物及其治疗用途
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
PT1355669E (pt) 2000-08-10 2012-01-02 Cold Spring Harbor Lab Treino cognitivo aumentado
US6815448B2 (en) * 2001-05-07 2004-11-09 Wyeth Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
PT1775298E (pt) 2004-07-01 2013-06-12 Daiichi Sankyo Co Ltd Derivado de tienopirazol com atividade inibidora da pde 7
WO2006092691A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
AU2008254907A1 (en) 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of identifying genes involved in memory formation using small interfering RNA(siRNA)
CA2687944A1 (en) 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
EP3652180B1 (en) 2017-07-12 2023-11-29 Dart NeuroScience, LLC Substituted benzoxazole and benzofuran compounds as pde7 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074754A1 (en) * 2001-03-21 2002-09-26 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
WO2007063391A2 (en) * 2005-12-02 2007-06-07 Pfizer Limited Spirocyclic quinazoline derivatives as pde7 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERNARDELLI, P. et al, "Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives", Bioorg. Med. Chem. Lett., 2004, vol. 14, no. 18, pages 4627-4631 *

Also Published As

Publication number Publication date
US20220267351A1 (en) 2022-08-25
KR102640696B1 (ko) 2024-02-27
MX2020000295A (es) 2020-07-22
EP3652180B1 (en) 2023-11-29
WO2019014305A1 (en) 2019-01-17
EP3652180A1 (en) 2020-05-20
US12319702B2 (en) 2025-06-03
US11685745B2 (en) 2023-06-27
CN111094293B (zh) 2025-08-01
JP7213863B2 (ja) 2023-01-27
CA3069432A1 (en) 2019-01-17
US20240199643A1 (en) 2024-06-20
AU2018300091A1 (en) 2020-01-30
KR20200027994A (ko) 2020-03-13
CN111094293A (zh) 2020-05-01
JP2020526546A (ja) 2020-08-31

Similar Documents

Publication Publication Date Title
AU2013277294B2 (en) Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
US12319702B2 (en) Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
US12006325B2 (en) Substituted furanopyrimidine compounds as PDE1 inhibitors
HK40006641A (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
HK40006641B (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
HK40036192A (en) Substituted furanopyrimidine compounds as pde1 inhibitors
HK40036192B (en) Substituted furanopyrimidine compounds as pde1 inhibitors
HK1208024B (en) 6-benzyl-6h-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (pde-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders
HK1208023B (en) 6-benzyl-6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c] pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c] pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)